Blocking the signal, not strengthening it, quiets the inflammation
At Weill Cornell Medicine, researchers have upended a foundational assumption of immunology — that tolerance requires activation — by discovering that blocking a key immune signal, rather than amplifying it, is what allows the gut to maintain peace with the microbial world it inhabits. Published in the Journal of Experimental Medicine, the finding reframes decades of therapeutic logic and illuminates why a promising drug failed in clinical trials over a decade ago. In doing so, it opens a quieter, more counterintuitive path toward treating inflammatory bowel disease, food allergies, and the collateral damage of cancer immunotherapy — a reminder that in complex biological systems, restraint can be more powerful than force.
- Millions living with Crohn's disease and ulcerative colitis have long awaited a treatment breakthrough, and a misfired drug trial from 2012 has quietly haunted the field ever since.
- Weill Cornell researchers discovered that blocking — not activating — a critical immune signaling step paradoxically multiplies the gut's tolerance-enforcing cells and damps chronic inflammation.
- The failed drug abatacept turns out to have been right in principle but wrong in context: IBD patients lack the very immune cells the drug depends on, rendering it inert in an already depleted gut.
- Scientists are now pursuing two corrective strategies — replenishing the missing cellular infrastructure before treatment, or administering the drug during remission when that infrastructure is still intact.
- The mechanism's reach extends beyond IBD, with implications for food allergy prevention and reducing the inflammatory side effects that undermine cancer immunotherapy.
For decades, immunologists assumed that promoting tolerance meant activating the right signals. Weill Cornell Medicine researchers have now inverted that logic entirely. In work published in the Journal of Experimental Medicine, a team led by Dr. Mengze Lyu and Dr. Gregory Sonnenberg found that blocking a critical immune signal — not strengthening it — is what actually quiets chronic gut inflammation and builds tolerance.
The gut faces a relentless stream of foreign material: bacteria, food proteins, microbial byproducts. In healthy individuals, a specialized population of regulatory T cells bearing the RORγt marker enforces a kind of cellular diplomacy, distinguishing threat from harmless presence. The Sonnenberg lab had previously identified a matching population of antigen-presenting cells, also RORγt-marked, that cluster in intestinal tissue and appear to instruct those Treg cells. The researchers set out to understand the signal exchanged between them.
T cell activation normally follows two steps. Signal One involves an antigen-presenting cell displaying a molecular fragment; Signal Two involves receptor interactions long considered essential for T cell expansion. The team expected the gut to follow the same rules. Instead, blocking Signal Two while preserving Signal One increased RORγt+ Treg cell numbers and protected against intestinal inflammation — the opposite of what the textbooks predicted.
This reframes a clinical disappointment that had lingered without explanation. Abatacept, a drug that blocks Signal Two, failed in IBD trials in 2012. The new research reveals why: IBD patients have depleted populations of the RORγt+ antigen-presenting cells needed to deliver Signal One in the first place. Without that cellular foundation, blocking Signal Two accomplishes nothing. The drug was sound in principle — it simply arrived at a gut that could no longer support it.
Dr. Lyu now sees two viable paths: restore the missing antigen-presenting cells, or time abatacept administration during remission, when those cells are still present. Because RORγt+ Treg cells also guard against food allergies and the inflammatory side effects of cancer immunotherapy, the implications reach well beyond IBD. The discovery reframes not just a failed trial, but a broader therapeutic philosophy — suggesting that in the immune system, as in much of biology, the most powerful intervention is sometimes knowing when to let go.
For decades, immunologists have operated from a straightforward assumption: to make the immune system more tolerant, you activate the right signals. Weill Cornell Medicine researchers just turned that logic inside out. In work published in April in the Journal of Experimental Medicine, they found that blocking a critical immune signal—not strengthening it—actually promotes tolerance in the gut and quiets chronic inflammation.
The discovery centers on how the intestinal immune system learns to coexist with trillions of harmless bacteria and food proteins without mounting an attack. The gut faces a constant barrage of foreign material, yet most people's bodies manage the distinction between threat and benign presence without incident. When that system fails, the result is inflammatory bowel disease—conditions like Crohn's disease and ulcerative colitis that affect millions of Americans. The Weill Cornell team, led by Dr. Mengze Lyu and senior researcher Dr. Gregory Sonnenberg, set out to understand the cellular conversation that maintains this delicate balance.
Previous work had identified a specialized subset of immune cells called RORγt+ regulatory T cells, or Treg cells, that live in the gut and enforce tolerance. The Sonnenberg lab had also discovered a unique population of antigen-presenting cells—the cells that show T cells what to tolerate—that also carry the RORγt marker and cluster in intestinal tissue. The question became: what signal passes between these two cell types to keep the peace?
T cell activation typically follows a two-step process. Signal One occurs when an antigen-presenting cell displays a molecular fragment to a T cell. Signal Two involves receptor interactions between the two cells and has long been considered essential for T cell expansion everywhere in the body. The researchers expected Signal Two to work the same way in the gut. Instead, they found something counterintuitive: blocking Signal Two while keeping Signal One intact actually increased the numbers of RORγt+ Treg cells and protected against intestinal inflammation in their preclinical model. The opposite of what textbooks predicted.
This finding reframes an earlier clinical disappointment. A drug called abatacept, or CTLA4-Ig, blocks the Signal Two interaction. When tested in IBD patients in 2012, it failed to improve outcomes. The new research suggests why: people with inflammatory bowel disease have fewer of the RORγt+ antigen-presenting cells needed to deliver Signal One. Without those cells present and functional, blocking Signal Two alone cannot work. The drug was correct in principle but arrived at a gut already depleted of the cellular infrastructure it needed.
Dr. Lyu proposed a path forward: restore the missing antigen-presenting cells, or administer abatacept to patients during remission when those cells are still present. The team is now pursuing both angles. Because RORγt+ Treg cells also protect against food allergies and the inflammatory side effects of cancer immunotherapy, the implications extend beyond IBD. A single mechanism, properly understood and properly timed, might address multiple chronic inflammatory conditions. The discovery does more than explain a failed drug trial. It suggests that sometimes the way to strengthen tolerance is not to push harder on the accelerator, but to release the brake.
Citações Notáveis
This is a paradigm-shifting discovery that will lead to new treatment approaches for chronic inflammatory disorders of the intestine— Dr. Gregory Sonnenberg, Weill Cornell Medicine
CTLA4-Ig could be effective against inflammatory bowel disease if we could restore the missing immune cells or give it to patients in remission when those cells are still present— Dr. Mengze Lyu, Weill Cornell Medicine
A Conversa do Hearth Outra perspectiva sobre a história
Why did blocking a signal work when activating it should have?
Because the gut's immune system operates by different rules than the rest of the body. In most tissues, Signal Two drives T cell expansion. In the intestine, it actually suppresses the specific tolerance cells you need. It's like the gut evolved a reverse logic.
So the drug abatacept was right, just in the wrong patient?
Exactly. It blocks Signal Two perfectly. But in IBD patients, the cells that deliver Signal One—the antigen-presenting cells—are already depleted. You're blocking the second step of a conversation where the first speaker has already left the room.
Can you restore those cells?
That's what they're testing now. Or you could give the drug earlier, when those cells are still present and functional. Timing and cellular context matter as much as the drug itself.
Does this change how we think about immune tolerance more broadly?
It challenges the assumption that tolerance works the same way everywhere. The gut is its own ecosystem. What we learn here might apply to food allergies or cancer immunotherapy side effects, but each tissue may have its own logic.
What's the risk if this works?
The main risk is that you're deliberately dampening immune responses in an organ constantly exposed to potential pathogens. You'd need to be careful about infections. But the fact that the gut naturally uses this mechanism suggests it's evolved to be safe.